KBC Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

KBC Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$66K	Hold	6,947	–	–	﹤0.01%	1538
2025 Q4	$54K	Hold	6,947	–	–	﹤0.01%	1611
2025 Q3	$53K	Hold	6,947	–	–	﹤0.01%	1627
2025 Q2	$62K	Sell	6,947 -3,251	-32%	-$30.3K	﹤0.01%	1482
2025 Q1	$76K	Hold	10,198	–	–	﹤0.01%	1624
2024 Q4	$77K	Buy	10,198 +4,537	+80%	+$34.4K	﹤0.01%	1691
2024 Q3	$43K	Sell	5,661 -2,974	-34%	-$22.6K	﹤0.01%	1765
2024 Q2	$53K	Buy	+8,635	New	+$47.7K	﹤0.01%	1579

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

KBC Group's BCRX Position: Q1 2026 in Review

KBC Group held its BioCryst Pharmaceuticals (BCRX) position steady in Q1 2026 at 6,947 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

KBC Group first reported a position in BCRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $77K in Q4 2024. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

KBC Group held 6,947 shares of BioCryst Pharmaceuticals worth $66K as of Q1 2026.
KBC Group left its BioCryst Pharmaceuticals share count unchanged in Q1 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1538 holding.
KBC Group first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
KBC Group's BioCryst Pharmaceuticals position peaked at $77K in Q4 2024.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.